Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 43.21B | 42.88B | 42.86B | 44.91B | 39.21B | 32.22B |
Gross Profit | 17.10B | 17.73B | 17.19B | 19.01B | 19.63B | 16.03B |
EBITDA | 11.40B | 11.80B | 11.20B | 11.94B | 11.97B | 10.11B |
Net Income | 6.58B | 6.33B | 6.00B | 6.95B | 7.72B | 6.38B |
Balance Sheet | ||||||
Total Assets | 101.23B | 97.32B | 98.73B | 97.15B | 95.12B | 69.05B |
Cash, Cash Equivalents and Short-Term Investments | 6.39B | 5.57B | 8.08B | 8.52B | 4.48B | 10.32B |
Total Debt | 35.23B | 32.77B | 36.42B | 36.07B | 36.34B | 22.55B |
Total Liabilities | 50.63B | 47.65B | 51.88B | 53.01B | 54.15B | 34.53B |
Stockholders Equity | 50.51B | 49.58B | 46.73B | 43.98B | 40.79B | 34.51B |
Cash Flow | ||||||
Free Cash Flow | 6.17B | 7.27B | 6.93B | 6.91B | 7.02B | 6.82B |
Operating Cash Flow | 7.58B | 8.67B | 8.41B | 9.15B | 9.54B | 8.29B |
Investing Cash Flow | -4.37B | -5.84B | -5.14B | -2.16B | -21.93B | -1.51B |
Financing Cash Flow | -5.95B | -6.79B | -3.62B | -2.81B | 6.58B | 959.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | $32.44B | 26.61 | 19.80% | ― | 3.53% | -10.72% | |
79 Outperform | $35.50B | 29.36 | 19.88% | 0.78% | 4.48% | -11.52% | |
78 Outperform | $186.06B | 28.22 | 13.44% | 0.34% | 2.05% | 7.03% | |
77 Outperform | $51.77B | 53.22 | 64.87% | ― | 6.68% | 18.84% | |
70 Outperform | $17.65B | 26.15 | 37.03% | ― | 5.89% | 10.61% | |
69 Neutral | $147.38B | 43.28 | 6.68% | 0.59% | -3.24% | -16.60% | |
51 Neutral | $7.90B | -0.33 | -41.69% | 2.23% | 23.45% | -1.99% |
On September 2, 2025, Thermo Fisher Scientific completed its $4.0 billion acquisition of Solventum Corporation’s purification and filtration business, enhancing its bioprocessing and adjacent market offerings. The acquisition is expected to generate $750 million in revenue for 2025 and provide significant growth and synergy opportunities, although it will initially be dilutive to adjusted EPS by $0.06. The transaction strengthens Thermo Fisher’s portfolio with advanced filtration technologies, expanding its reach in industries requiring ultra-pure water, such as battery, semiconductor, and medical device manufacturing.
On July 23, 2025, Thermo Fisher Scientific Inc. announced that its Senior Vice President and Chief Financial Officer, Stephen Williamson, will retire effective March 31, 2026. James R. Meyer, currently Vice President of Financial Operations, will succeed Williamson as CFO starting March 1, 2026, bringing extensive experience within the company since joining in 2009.